The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Hyperthermic intraperitoneal chemotherapy (HIPEC) is an innovative treatment approach used in the management of ovarian cancer, particularly in advanced stages. This technique involves delivering ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

Neoadjuvant chemotherapy for advanced ovarian cancer was initially ... and extended target diseases to not only ovarian cancer but also tubal and peritoneal cancers. The results of the first ...

At the Research Awards 2024, we had the pleasure of hearing from Professor Anna DeFazio AM, University of Sydney, who heads ...

A single-arm Phase II trial of vintafolide (EC-FV-02) was subsequently conducted in patients with recurrent/persistent ovarian, fallopian tube and primary peritoneal cancer, as well as endometrial ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

While peritoneal and ovarian cancers are similar ... treatment that has proven beneficial for peritoneal cancer. During this procedure, chemotherapy drugs are heated to 107.6 degrees F prior ...

IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing authorisation for Senaparib capsules to treat ovarian cancer. The authorisation allows the ...

The benefits of HIPEC include improved local control of cancer, reduced recurrence rates, and enhanced survival outcomes for ...